Back to results
US 7,067,538 B2Granted
MCP-1 receptor antagonists and methods of use thereof
AssigneeWarner-Lambert Company
InventorsLarry D. Bratton, Alexander J. Bridges, David T. Connor, Steven R. Miller, Yuntao Song, Kuai-Lin Sun, Bharat K. Trivedi, Paul C. Unangst
Life of this patent
Estimating the term…
Abstract
The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.
Claims15
A compound of Formula I or II:
- or a pharmaceutically acceptable salt of a compound of Formula I or II;
- wherein:
- D is (CH2)n, where n is 0 or 1;
- R1, R2, R3, and R4 are each independently selected from the group consisting of:
- H, C1–C6alkyl, C3–C6cycloalkyl, C3–C6heterocycloalkyl, phenyl, halogen, and CF3;
- W is N, CH, or CF;
- R5 and R6 are each independently H or F;
- Z is selected from the group consisting of:
- C1–C6 alkyl, CH2Br, CH2Cl, CF3, CH2F, CHF2, CH2R7, CFR7R8, CF2R7, CH2OR7, CHFOR7, CF2OR7, C(O)NR7R8, CO2R7,
- phenyl, C6–C12aryl, and C5–C12heteroaryl;
- R7, R8, and R9, are independently selected from the group consisting of H, C1–C6alkyl, CF3, CCl3, C6–C12aryl, C6–C12aryl-C1–C6alkyl-, C5–C12heteroaryl, and C5–C12heteroaryl-C1–C6alkyl-;
- R10 and R12 are independently selected from the group consisting of F, H, C1–C6alkyl, CF3, CCl3, C6–C12aryl, C6–C12aryl-C1–C6alkyl-, C5–C12heteroaryl, and C5–C12heteroaryl-C1–C6alkyl-;
- and
- wherein 2-(diphenyl-methanesulfonyl)-1-pyridin-2-yl-ethanone is not included.
11 more elements
A method for treating a chemokine associated disorder in a subject comprising administering to the subject an effective amount of a compound of Formula I or II:
- or a pharmaceutically acceptable salt of a compound of Formula I or II;
- wherein:
- D is (CH2)n, where n is 0 or 1;
- R1, R2, R3, and R4 are each independently selected from H, C1–C6alkyl, C3–C6cycloalkyl, C3–C6heterocycloalkyl, phenyl, halogen, or CF3;
- W is N, CH, or CF;
- R5 and R6 are independently H or F;
- Z is selected from the group consisting of:
- C1–C6 alkyl, CH2Br, CH2Cl, CF3, CH2F, CHF2, CH2R7, CFR7R8, CF2R7, CH2OR7, CHFOR7, CF2OR7, C(O)NR7R8, CO2R7,
- phenyl, C6–C12aryl, and C5–C12heteroaryl;
- R7, R8, and R9, are independently selected from the group consisting of H, C1–C6 alkyl, CF3, CCl3, C6–C12aryl, C6–C12aryl-C1–C6 alkyl-, C5–C12heteroaryl, and C5–C12heteroaryl-C1–C6alkyl-;
- R10 and R12 are independently selected from the group consisting of F, H, C1–C6 alkyl, CF3, CCl3, C6–C12aryl, C6–C12aryl-C1–C6 alkyl-, C5–C12heteroaryl, and C5–C12heteroaryl-C1–C6alkyl-;
- and
- wherein 2-(diphenyl-methanesulfonyl)-1-pyridin-2-yl-ethanone is not included.
10 more elements
Dependencies are inferred from the claim text.